MX2021001545A - Péptidos penetrantes celulares. - Google Patents

Péptidos penetrantes celulares.

Info

Publication number
MX2021001545A
MX2021001545A MX2021001545A MX2021001545A MX2021001545A MX 2021001545 A MX2021001545 A MX 2021001545A MX 2021001545 A MX2021001545 A MX 2021001545A MX 2021001545 A MX2021001545 A MX 2021001545A MX 2021001545 A MX2021001545 A MX 2021001545A
Authority
MX
Mexico
Prior art keywords
peptides
penetrating peptides
cell
conjugates
treatment
Prior art date
Application number
MX2021001545A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Wood
Raquel Manzano
Caroline Godfrey
Graham Mcclorey
Richard Raz
Michael Gait
Andrey Arzumanov
Liz O''DONOVAN
Gareth Hazell
Ashling Holland
Miguel Varela
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2021001545A publication Critical patent/MX2021001545A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021001545A 2018-08-09 2019-08-09 Péptidos penetrantes celulares. MX2021001545A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1812972.6A GB201812972D0 (en) 2018-08-09 2018-08-09 Cell-penetrating peptides
PCT/GB2019/052247 WO2020030927A1 (en) 2018-08-09 2019-08-09 Cell-penetrating peptides

Publications (1)

Publication Number Publication Date
MX2021001545A true MX2021001545A (es) 2021-08-24

Family

ID=63667311

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021001545A MX2021001545A (es) 2018-08-09 2019-08-09 Péptidos penetrantes celulares.
MX2026000051A MX2026000051A (es) 2018-08-09 2021-02-08 Peptidos penetrantes celulares

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2026000051A MX2026000051A (es) 2018-08-09 2021-02-08 Peptidos penetrantes celulares

Country Status (12)

Country Link
US (2) US12268749B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833376A1 (cg-RX-API-DMAC7.html)
JP (2) JP7663492B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210090157A (cg-RX-API-DMAC7.html)
CN (1) CN113347989A (cg-RX-API-DMAC7.html)
AU (2) AU2019317789B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002447A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108876A1 (cg-RX-API-DMAC7.html)
GB (1) GB201812972D0 (cg-RX-API-DMAC7.html)
IL (2) IL280678B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021001545A (cg-RX-API-DMAC7.html)
WO (1) WO2020030927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
AU2019394177A1 (en) 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
CA3211038A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
US20240200062A1 (en) * 2021-03-12 2024-06-20 Pepgen Inc. Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates
AU2022298774A1 (en) * 2021-06-23 2023-12-14 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
WO2025264554A1 (en) 2024-06-17 2025-12-26 Pepgen Inc. Antisense oligonucleotide conjugates targeting peripheral myelin protein 22 (pmp22) and methods of use thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518521A (ja) 1998-06-20 2002-06-25 ワシントン・ユニバーシティ 医用画像解析、診断および治療のための膜透過性ペプチド錯体
IL127773A0 (en) 1998-12-28 1999-10-28 Yeda Res & Dev Saccharide conjugates and pharmaceutical compositions comprising them
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
AU2004235396B2 (en) 2003-04-29 2010-11-25 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
ES2627917T3 (es) 2004-06-28 2017-08-01 The University Of Western Australia Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
IE20060565A1 (en) 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
WO2008109105A2 (en) 2007-03-06 2008-09-12 Flagship Ventures Methods and compositions for improved therapeutic effects with sirna
US20080306001A1 (en) 2007-04-04 2008-12-11 Anzelika Liik Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
CA2691673A1 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2249851B1 (en) 2008-02-13 2015-04-01 Kao Corporation Method for producing hippocastanaceae plant seed extract
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
WO2009147368A1 (en) * 2008-06-04 2009-12-10 Medical Research Council Peptides
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
EP3133160B1 (en) 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
SI2607484T1 (sl) 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
HUE040445T2 (hu) 2009-11-12 2019-03-28 Univ Western Australia Antiszensz molekulák és eljárások betegségek kezelésére
NZ704191A (en) 2010-06-14 2016-05-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
EP2394665A1 (en) * 2010-06-14 2011-12-14 F. Hoffmann-La Roche AG Cell-penetrating peptides and uses therof
ES2756326T3 (es) 2010-07-19 2020-04-27 Ionis Pharmaceuticals Inc Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスBionor Immuno As ペプチド骨格設計
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
AU2011367230B2 (en) 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2013030569A2 (en) * 2011-08-30 2013-03-07 Michael John Gait Peptides
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
BR112014027239A2 (pt) 2012-06-26 2017-07-18 Hoffmann La Roche peptídeo, método de identificação de peptídeos, método para o tratamento de câncer, nucleotídeo, vetor, uso de um peptídeo e invenção
AU2013316679B2 (en) 2012-09-13 2017-12-14 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US10111962B2 (en) 2012-09-25 2018-10-30 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
EP3760720A1 (en) 2013-03-14 2021-01-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
GB201314411D0 (en) * 2013-08-12 2013-09-25 Medical Res Council Peptide conjugates
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
US10358643B2 (en) 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
WO2015161255A1 (en) 2014-04-18 2015-10-22 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
GB201421379D0 (en) 2014-12-02 2015-01-14 Isis Innovation Ltd And Medical Res Council Molecule
EP3034074A1 (en) 2014-12-18 2016-06-22 Universitat De València, Estudi General Compound for treatment of myotonic dystrophy type 1
US10017542B2 (en) 2015-03-23 2018-07-10 Riptide Bioscience, Inc. Antimicrobial peptides and methods of use thereof
JP6817288B2 (ja) 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
US10858410B2 (en) 2015-08-12 2020-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
JP2018530560A (ja) 2015-10-09 2018-10-18 サレプタ セラピューティクス, インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
DK3463308T4 (da) 2016-06-01 2026-02-09 Servier Ip Uk Ltd Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
CN110392583B (zh) 2016-09-15 2023-01-03 加利福尼亚大学董事会 改进的杂化的末端树枝状聚合物
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
JP2020536058A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法
JP2020536060A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法
EP3687519A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
AU2019394177A1 (en) 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
WO2020214763A1 (en) 2019-04-18 2020-10-22 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
EP3987029A1 (en) 2019-06-19 2022-04-27 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
EP3997228A4 (en) 2019-07-09 2024-05-15 The Governors of the University of Alberta SKIP OF EXONS 45 TO 55 USING MUTATION-ADAPTED COCKTAILS, OF ANTISENS MORPHOLINOS, IN THE DMD GENE
GB201911403D0 (en) 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
US20240189434A1 (en) 2021-03-12 2024-06-13 Pepgen Inc. Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates
US20240200062A1 (en) 2021-03-12 2024-06-20 Pepgen Inc. Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates

Also Published As

Publication number Publication date
IL280678B2 (en) 2025-07-01
GB201812972D0 (en) 2018-09-26
JP7663492B2 (ja) 2025-04-16
US12268749B2 (en) 2025-04-08
IL318744A (en) 2025-04-01
BR112021002447A2 (pt) 2021-05-04
AU2025263913A1 (en) 2025-12-18
JP2021534131A (ja) 2021-12-09
US20250387498A1 (en) 2025-12-25
IL280678B1 (en) 2025-03-01
MX2026000051A (es) 2026-02-03
CN113347989A (zh) 2021-09-03
AU2019317789A1 (en) 2021-03-04
US20210299263A1 (en) 2021-09-30
AU2019317789B2 (en) 2025-08-14
WO2020030927A1 (en) 2020-02-13
CA3108876A1 (en) 2020-02-13
KR20210090157A (ko) 2021-07-19
EP3833376A1 (en) 2021-06-16
JP2025106403A (ja) 2025-07-15
IL280678A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MX2026000051A (es) Peptidos penetrantes celulares
MX2021001546A (es) Péptidos penetrantes celulares.
EP4501352A3 (en) Compositions and methods for car t cell therapy
WO2017177149A3 (en) Methods and compositions for car t cell therapy
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
EP4523696A3 (en) Enhanced adoptive cell therapy
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
EP3611184C0 (en) CELL PENETRATING PEPTIDE, CONJUGATE COMPRISING SAME, AND COMPOSITION COMPRISING THE CONJUGATE
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
CL2011001392A1 (es) Compuestos derivados de pteridinona, moduladores de receptores tipo toll; composicion farmaceutica que lo comprende, util en el tratamiento de una infeccion viral, cancer, asma, entre otras.
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
BR112012020863A2 (pt) formas de rifaximina e usos das mesmas
BR112018008017A2 (pt) composição farmacêutica, método de preparação de composição farmacêutica líquida, kit farmacêutico, sistema de fornecimento de injeção
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
AU2017250507A8 (en) Methods of treatment using chlorotoxin conjugates
UA115135C2 (uk) Катіонні полімери на основі глікогену
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
CU20190078A7 (es) Péptidos útiles en el tratamiento de diabetes
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
BR112014021602A2 (pt) uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide